A Spravato Overview of Dosage and Administration
Spravato is the brand name for esketamine, a prescription medication delivered as a nasal spray. It is derived from ketamine and is regulated for use in supervised clinical settings. Patients self-administer the spray under the observation of a healthcare provider, typically in a certified medical office or clinic. Because the medication is given in a controlled environment, the experience differs from taking a standard prescription at home. Here’s information on Spravato dosing and administration:
Who Esketamine May Benefit
Esketamine is prescribed most often for adults who have tried other treatment approaches for depression without effective results. A psychiatrist reviews a person’s medical history, current medications, and overall health before recommending it. Esketamine spray is typically discussed with individuals diagnosed with treatment-resistant depression (TRD), a severe condition where traditional antidepressant medications and therapy have been ineffective.
Esketamine treatments, like Spravato, are not suitable for everyone, and certain medical conditions may rule them out. The decision involves a careful conversation between the patient and the prescribing clinician. This option is recommended when patients have tried at least two different antidepressant treatments at adequate dosages and durations without experiencing sufficient improvement. It may also be recommended for individuals who exhibit a high risk of suicide and require rapid symptom relief. The decision to use Spravato takes into account the patient’s health factors, their response to prior treatments, and the potential benefits versus risks of this therapy.
What To Expect During Administration
Spravato treatment takes place in a certified setting, where a patient remains for the full session. In a medical office, the patient receives instructions on using the nasal spray device, and a provider observes each step. The esketamine spray is administered to both nostrils according to the prescribed amount. Once the dose is taken, the individual will stay in the office for a monitoring period that commonly lasts about two hours. Medical staff will check blood pressure and watch for any reactions during this time.
Some people report temporary side effects while the medication is active, such as:
- Dizziness
- A Sense of Detachment
- Perception Changes
Because of these possible effects, someone cannot drive themself home after their session. To be proactive, arrange a ride or other transportation beforehand and avoid operating machinery for the rest of the day. Many patients schedule sessions earlier in the day so they can rest afterward. A provider will confirm when the patient is stable before they can leave their session.
Where the Dosage Starts
The frequency of sessions follows a schedule set by the psychiatrist. Early in a treatment plan, appointments may occur more often, but the spacing often changes as treatments continue. Spravato doses begin at 28 mg, administered as 14 mg per nostril. This starting amount gives the clinician a baseline to observe how a patient tolerates the medication during the initial session. The provider notes any effects and reviews the individual’s vital signs throughout the monitoring window to oversee safety. A dose may be increased in later sessions, but only under clinician supervision and based on individual response.
Learn More About Spravato From a Psychiatrist
Spravato treatments follow a structured process that includes supervised administration, a monitoring period, and dosing decisions made by a clinician. Understanding the general routine can help you prepare practical details, such as arranging transportation and setting aside time for each visit. Because individual circumstances vary, the most reliable information comes from a qualified provider who can review your specific situation. To learn if esketamine is appropriate for your situation, schedule a consultation with a psychiatrist to discuss your needs today.
